Mass cytometry-based analysis of the composition of the immune system in peripheral blood and cerebrospinal fluid in narcolepsy

Mass cytometry-based analysis of the composition of the immune system in peripheral blood and cerebrospinal fluid in narcolepsy - Immune system composition in narcolepsy patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45374

Enrollment

Registered

2017-11-02

Start date

2017-12-19

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

narcolepsy sleep disorders

Interventions

Immune system

Mass cytometry

Narcolepsy

Peripheral blood

Eligibility

Age

12 Years to 64 Years

Inclusion criteria

Inclusion criteria: Diagnosed with narcolepsy type 1 according to ICSD-3 criteria (international criteria for sleep disorders, third edition) Symptom onset = 12 years (patient), >= 18 years (control)

Exclusion criteria

Exclusion criteria: Patients and healthy controls: Recent use (=12).

Design outcomes

Primary

Measure	Time frame
Which immune cell populations are significantly different in peripheral blood of type 1 narcolepsy patients compared with healthy controls using mass cytometry and an antibody panel consisting of 36 cell surface markers?	—

Secondary

Measure	Time frame
Is the specific immune system composition in peripheral blood in narcolepsy type 1 reflected in CSF, using flow cytometryand cerebrospinal fluid of narcolepsy patients?	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)